-

CHEMOCENTRYX 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. - CCXI

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until July 6, 2021 to file lead plaintiff applications in securities class action lawsuits against ChemoCentryx, Inc. (NasdaqGS: CCXI), if they purchased the Company’s shares between November 26, 2019 and May 6, 2021, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased shares of ChemoCentryx and would like to discuss your legal rights and how these cases might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ccxi/ to learn more. If you wish to serve as a lead plaintiff in the class actions, you must petition the Courts by July 6, 2021.

About the Lawsuits

ChemoCentryx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On May 4, 2021, the U.S. Food and Drug Administration issued briefing documents regarding the Company’s drug candidate, avacopan, noting that “[c]omplexities of the study design…raise questions about the interpretability of the data to define a clinically meaningful benefit of avacopan” and that the review had “identified several areas of concern, raising uncertainty about the interpretability of the data and the clinical meaningfulness of these results.” On this news, shares of ChemoCentryx plummeted approximately 45%, to close at $26.63 per share on May 4, 2021.

The first-filed case is Homyk v. ChemoCentryx, Inc., et al., No. 3:21-cv-03343.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Kahn Swick & Foti, LLC

NASDAQ:CCXI

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Blue Owl Technology Finance Corp. Securities Class Action Filed on Behalf of Former OTF II Shareholders Following Nearly 44% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., announce that a securities class action lawsuit has been filed against Blue Owl Technology Finance Corp. (NYSE: OTF) (“OTF” or the “Company”) on behalf of all former shareholders of Blue Owl Technology Finance Corp. II (“OTF II”) who received shares of OTF common stock in direct exchange for their OTF II shares in the March 24, 2025 merger by w...

Lumentum Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lumentum Holdings Inc. - LITE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lumentum Holdings Inc. (NasdaqGS: LITE) to Marvell Technology, Inc. (NasdaqGS: MRVL). Under the terms of the proposed transaction, shareholders of Lumentum will receive 4.500 shares of Marvell common stock for each share of Lumentum that they own. KSF is seeking to determine whether this considerati...

Manhattan Associates Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Manhattan Associates, Inc. - MANH

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Manhattan Associates, Inc. (“Manhattan”) (NasdaqGS: MANH).Manhattan is a global software company that sells solutions for managing supply chains, inventory, and omnichannel operations, and also provides services to implement, customize, and upgrade its software products. A securities...
Back to Newsroom